Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Share Price Pass Below 200 Day Moving Average – Here’s What Happened

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $31.45 and traded as low as $27.24. Lakefront Biotherapeutics American Depositary Shares shares last traded at $27.67, with a volume of 69,614 shares.

Analyst Ratings Changes

LKFT has been the subject of a number of recent research reports. Royal Bank Of Canada upped their price target on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 24th. UBS Group reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Zacks Research downgraded Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Raymond James Financial reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Finally, Weiss Ratings raised Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

The company has a market cap of $1.82 billion, a price-to-earnings ratio of -19.62 and a beta of 0.25. The firm has a fifty day moving average price of $28.97 and a 200 day moving average price of $31.45.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The company had revenue of $1.06 billion during the quarter. On average, analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several large investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 2.1% in the 3rd quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock valued at $1,072,000 after buying an additional 643 shares during the last quarter. Van ECK Associates Corp boosted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% in the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 750 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 3.7% in the 3rd quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 800 shares during the last quarter. State of Wyoming acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter valued at approximately $28,000. Finally, Arax Advisory Partners boosted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% in the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 1,778 shares during the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.